04:28 PM EDT, 06/30/2025 (MT Newswires) -- Nektar Therapeutics ( NKTR ) said late Monday it has launched an underwritten public offering of common shares and pre-funded warrants.

The biotechnology company plans to offer underwriters a 30-day overallotment option to buy up to an additional 15% of shares at the public offering price, excluding underwriting discounts and commissions.

Nektar plans to use the net proceeds for general corporate purposes, which may include funding research and clinical development, covering manufacturing expenses to advance its drug candidates, and supporting other routine business operations.

Shares of Nektar were down 3.2% in after-hours activity.

Price: 25.02, Change: -0.82, Percent Change: -3.17